Keynote address: cellular reduction of nitroimidazole drugs: potential for selective chemotherapy and diagnosis of hypoxic cells
Journal Article
·
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
Nitroimidazole drugs were initially developed as selective radiosensitizers of hypoxic cells and, consequently, as adjuvants to improve the local control probabilities of current radiotherapies. Misonidazole (MISO), the prototype radiosensitizing drug, was found in Phase I clinical studies to cause dose-limiting neurotoxicities (mainly peripheral neuropathies). MISO was also found to be cytotoxic in the absence of radiation and to covalently bind to cellular molecules, both processes demonstrating rates much higher in hypoxic compared with oxygenated cells. It is likely that neurotoxicity, cellular cytotoxicity and adduct formation results from reactions between reduction intermediates of MISO and cellular target molecules. Spin-offs from radiosensitizer research include the synthesis and characterization of more potent hypoxic cytotoxins and the exploitation of sensitizer-adducts as probes for measuring cellular and tissue oxygen levels. Current developments in hypoxic cell cytotoxin and hypoxic cell marker research are reviewed with specific examples from studies which characterize the cellular reduction of TF-MISO, (1-(2-nitro-1-imidazolyl)-3(2,2,2-trifluoroethoxy)-2-propanol). 45 references.
- Research Organization:
- Cross Cancer Institute, Edmonton, Alberta (Canada)
- OSTI ID:
- 6097263
- Journal Information:
- Int. J. Radiat. Oncol., Biol. Phys.; (United States), Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Vol. 16:4; ISSN IOBPD
- Country of Publication:
- United States
- Language:
- English
Similar Records
Clinical perspectives for the use of new hypoxic cell sensitizers
Iodoazomycin riboside (1-(5'-iodo-5'-deoxyribofuranosyl)-2-nitroimidazole), a hypoxic cell marker. I. Synthesis and in vitro characterization
Azomycin riboside: a new radiosensitizer
Journal Article
·
Wed Sep 01 00:00:00 EDT 1982
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
·
OSTI ID:6866120
Iodoazomycin riboside (1-(5'-iodo-5'-deoxyribofuranosyl)-2-nitroimidazole), a hypoxic cell marker. I. Synthesis and in vitro characterization
Journal Article
·
Fri Jan 31 23:00:00 EST 1986
· Radiat. Res.; (United States)
·
OSTI ID:5617059
Azomycin riboside: a new radiosensitizer
Journal Article
·
Sun Feb 28 23:00:00 EST 1982
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
·
OSTI ID:6705691
Related Subjects
550603 -- Medicine-- External Radiation in Therapy-- (1980-)
560151* -- Radiation Effects on Animals-- Man
62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ANIMAL CELLS
ANOXIA
ANTINEOPLASTIC DRUGS
AZOLES
BIOCHEMICAL REACTION KINETICS
DOCUMENT TYPES
DRUGS
EVALUATION
EXPERIMENTAL NEOPLASMS
HETEROCYCLIC COMPOUNDS
IMIDAZOLES
KINETICS
MEDICINE
MISONIDAZOLE
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
RADIOLOGY
RADIOSENSITIZERS
RADIOTHERAPY
REACTION KINETICS
REVIEWS
THERAPY
TOXICITY
TUMOR CELLS
560151* -- Radiation Effects on Animals-- Man
62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ANIMAL CELLS
ANOXIA
ANTINEOPLASTIC DRUGS
AZOLES
BIOCHEMICAL REACTION KINETICS
DOCUMENT TYPES
DRUGS
EVALUATION
EXPERIMENTAL NEOPLASMS
HETEROCYCLIC COMPOUNDS
IMIDAZOLES
KINETICS
MEDICINE
MISONIDAZOLE
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
RADIOLOGY
RADIOSENSITIZERS
RADIOTHERAPY
REACTION KINETICS
REVIEWS
THERAPY
TOXICITY
TUMOR CELLS